A multicenter randomized control study of the effect of umbilical cord milking in avoiding red cell transfusions in extremely immature infants

A multicenter randomized control study of the effect of umbilical cord milking in avoiding red cell transfusions in extremely immature infants - A multicenter randomized control study of the effect of umbilical cord milking

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000990

Enrollment

566

Registered

2008-01-23

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extremely immature infants

Interventions

First, umbilical cord is cut and clamped at 30cm from infants. Next the baby is placed on a radiant wormer. Finally, a Pediatrician straightens a kink of the umbilical cord and then milks the umbilica

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) infants born at 24 to less than 28 weeks of gestation 2) informed cocents obtained from parents

Exclusion criteria

Exclusion criteria: 1) Major anomalies diagnosed in utero 2) intrauterin growth retardation ( less than 3SD) 3) monochorionic twins 4) super twin

Design outcomes

Primary

Measure	Time frame
1) the probability of not needing transfusion and death 2) amount of blood transfusion within the first 4 weeks	—

Secondary

Measure	Time frame
1) Mortality 2) Major complications (intraventricular hemorrage, chronic lung disease, periventricular leukomalasia, retionopath of prematurity, ontestinal perfolation) 3) serious adverse event 4) hemoglobin values within the first 24 hours 5) stabilization of blood pressure and use of volume expander and/or inotoropes 6) incidence of polycythemia and hyperbilirubinemia 7) developmental disorder at 18 months and 3 years of age (neurodevelopmental delay, cerebral palsy, epilepsy, visual impairment, hearing loss)	—

Measure

Time frame

1) Mortality 2) Major complications (intraventricular hemorrage, chronic lung disease, periventricular leukomalasia, retionopath of prematurity, ontestinal perfolation) 3) serious adverse event 4) hemoglobin values within the first 24 hours 5) stabilization of blood pressure and use of volume expander and/or inotoropes 6) incidence of polycythemia and hyperbilirubinemia 7) developmental disorder at 18 months and 3 years of age (neurodevelopmental delay, cerebral palsy, epilepsy, visual impairment, hearing loss)

—

Countries

Japan

Contacts

Public ContactShigeharu Hosono

Nihon University School of Medicine Department of Pediatrics and Child Health

hosonos@med.nihon-u.ac.jp03-3972-8111(2442)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026